Cargando…

Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System

The enclosed work focuses on the construction variables associated with a dual-antigen liposomal carrier, delivering encapsulated polysaccharides and surface-localized proteins, which served as a vaccine delivery device effective against pneumococcal disease. Here, the goal was to better characteriz...

Descripción completa

Detalles Bibliográficos
Autores principales: Nayerhoda, Roozbeh, Hill, Andrew, Beitelshees, Marie, Jones, Charles, Pfeifer, Blaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747791/
https://www.ncbi.nlm.nih.gov/pubmed/31480544
http://dx.doi.org/10.3390/ma12172809
_version_ 1783451975497547776
author Nayerhoda, Roozbeh
Hill, Andrew
Beitelshees, Marie
Jones, Charles
Pfeifer, Blaine
author_facet Nayerhoda, Roozbeh
Hill, Andrew
Beitelshees, Marie
Jones, Charles
Pfeifer, Blaine
author_sort Nayerhoda, Roozbeh
collection PubMed
description The enclosed work focuses on the construction variables associated with a dual-antigen liposomal carrier, delivering encapsulated polysaccharides and surface-localized proteins, which served as a vaccine delivery device effective against pneumococcal disease. Here, the goal was to better characterize and compare the carrier across a range of formulation steps and assessment metrics. Specifically, the vaccine carrier was subjected to new methods of liposomal formation, including alterations to the base components used for subsequent macromolecule encapsulation and surface attachment, with characterization spanning polysaccharide encapsulation, liposomal size and charge, and surface protein localization. Results demonstrate variations across the liposomal constructs comprised two means of surface-localizing proteins (either via metal or biological affinity). In general, final liposomal constructs demonstrated a size and zeta potential range of approximately 50 to 600 nm and −4 to −41 mV, respectively, while demonstrating at least 60% polysaccharide encapsulation efficiency and 60% protein surface localization for top-performing liposomal carrier constructs. The results, thus, indicate that multiple formulations could serve in support of vaccination studies, and that the selection of a suitable final delivery system would be dictated by preferences or requirements linked to target antigens and/or regulatory demands.
format Online
Article
Text
id pubmed-6747791
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67477912019-09-27 Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System Nayerhoda, Roozbeh Hill, Andrew Beitelshees, Marie Jones, Charles Pfeifer, Blaine Materials (Basel) Article The enclosed work focuses on the construction variables associated with a dual-antigen liposomal carrier, delivering encapsulated polysaccharides and surface-localized proteins, which served as a vaccine delivery device effective against pneumococcal disease. Here, the goal was to better characterize and compare the carrier across a range of formulation steps and assessment metrics. Specifically, the vaccine carrier was subjected to new methods of liposomal formation, including alterations to the base components used for subsequent macromolecule encapsulation and surface attachment, with characterization spanning polysaccharide encapsulation, liposomal size and charge, and surface protein localization. Results demonstrate variations across the liposomal constructs comprised two means of surface-localizing proteins (either via metal or biological affinity). In general, final liposomal constructs demonstrated a size and zeta potential range of approximately 50 to 600 nm and −4 to −41 mV, respectively, while demonstrating at least 60% polysaccharide encapsulation efficiency and 60% protein surface localization for top-performing liposomal carrier constructs. The results, thus, indicate that multiple formulations could serve in support of vaccination studies, and that the selection of a suitable final delivery system would be dictated by preferences or requirements linked to target antigens and/or regulatory demands. MDPI 2019-09-01 /pmc/articles/PMC6747791/ /pubmed/31480544 http://dx.doi.org/10.3390/ma12172809 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nayerhoda, Roozbeh
Hill, Andrew
Beitelshees, Marie
Jones, Charles
Pfeifer, Blaine
Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System
title Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System
title_full Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System
title_fullStr Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System
title_full_unstemmed Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System
title_short Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System
title_sort design variation of a dual-antigen liposomal vaccine carrier system
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747791/
https://www.ncbi.nlm.nih.gov/pubmed/31480544
http://dx.doi.org/10.3390/ma12172809
work_keys_str_mv AT nayerhodaroozbeh designvariationofadualantigenliposomalvaccinecarriersystem
AT hillandrew designvariationofadualantigenliposomalvaccinecarriersystem
AT beitelsheesmarie designvariationofadualantigenliposomalvaccinecarriersystem
AT jonescharles designvariationofadualantigenliposomalvaccinecarriersystem
AT pfeiferblaine designvariationofadualantigenliposomalvaccinecarriersystem